MOUNTAIN VIEW, CA — (Marketwired) — 04/26/16 — Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today provides an update on the status of its key corporate initiative to expand the utility and regulatory labeling of the Magellan product line.Hansen Medical recently submitted a 510k to the FDA for a neurological indication for the Magellan Robotic System. If successful, the Magellan Robotic System would be fully indicated for applications in peripheral va
MOUNTAIN VIEW, CA — (Marketwired) — 04/25/16 — Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it will exhibit its Magellan Robotic System at the Charing Cross International Symposium in London, United Kingdom from April 26th to April 29th.At the 38th annual symposium, the Magellan Robotic System and family of Magellan Robotic Catheters will be showcased and available for demonstrations at exhibit booth #215. Hansen Medical also anticipa
SAN CARLOS, CA and MOUNTAIN VIEW, CA — (Marketwired) — 04/20/16 — Auris Surgical Robotics, Inc. and Hansen Medical, Inc. (NASDAQ: HNSN) today announced that they have signed a definitive merger agreement under which Auris will acquire Hansen Medical for $4.00 per share in cash, or a total equity value of approximately $80 million. The purchase price per share represents a premium of approximately 39.9% over the closing sale price of common stock of Hansen Medical as reported on NASDAQ on Apr
MOUNTAIN VIEW, CA — (Marketwired) — 04/06/16 — Hansen Medical®, Inc. (NASDAQ: HNSN) today announced that it received a notification letter on March 31, 2016 from The NASDAQ Stock Market ("NASDAQ"). The notification letter stated that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2015 (the "Form 10-K"), the Company is no longer in compliance with NASDAQ Marketplace Rule 5250(c)(1), which requires timely filing of p
MOUNTAIN VIEW, CA — (Marketwired) — 03/17/16 — Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it will exhibit its Magellan Robotic System at the Annual Society of Interventional Radiology (SIR) Scientific Meeting April 2-7 in Vancouver, British Columbia, Canada. The Company will showcase the newly approved Magellan Robotic Catheter eKit that has been used by Interventional Radiologists in a variety of procedures, including Uterine Fibro
MOUNTAIN VIEW, CA — (Marketwired) — 02/17/16 — Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced the completion of the first clinical procedure in the United States with the Magellan Robotic Catheter eKit (MRC eKit). Interventional Radiologist, Dr. Ripal Gandhi, performed the procedure at Miami Cardiac & Vascular Institute (MCVI) in Miami, FL. Dr. Gandhi used the MRC eKit during a robotic transarterial chemoembolization (TACE) procedur
MOUNTAIN VIEW, CA — (Marketwired) — 02/02/16 — Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the Magellan Robotic Catheter eKit (MRC eKit). The MRC eKit is the company–s latest addition to the family of approved Magellan Robotic Catheters and helps extend robotic capabilities and control throughout procedures in the peripheral vasculature. With the MRC eKit, physici
MOUNTAIN VIEW, CA — (Marketwired) — 01/14/16 — Hansen Medical, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today provided an update of key corporate initiatives which, if successful, will expand the utility and regulatory labeling of the Sensei® and Magellan product lines:This study is a prospective, single arm study of the Hansen Sensei System for introducing and positioning RF ablation catheters in subjects with paroxysmal atrial fibrillation (PAF). As of January
MOUNTAIN VIEW, CA — (Marketwired) — 01/14/16 — Hansen Medical, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, announced today that its board of directors has entered a process to explore strategic alternatives for the company focused on enhancing stockholder value, including, but not limited to, a licensing transaction, a refinancing transaction, a strategic business combination, partnership, a possible sale or disposition of one or more corporate assets or the company its
